Mallinckrodt public limited company (MNK)
(Delayed Data from NYSE)
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel
Lessons from my Favorite Book for Value Investors
by Tracey Ryniec
Interested in drilling down deeper into value investing? This book offers a quick, and entertaining, overview of what it takes.
6 Valuable Price-to-Book Stocks to Buy as Slowdown Lurks
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
MNK vs. AMPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Mallinckrodt (MNK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Mallinckrodt (MNK) closed the most recent trading day at $23.58, moving -1.13% from the previous trading session.
Has Mallinckrodt public limited (MNK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MNK) Outperforming Other Medical Stocks This Year?
Is Mallinckrodt (MNK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt (MNK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Mallinckrodt (MNK) closed at $22.53, marking a -1.18% move from the previous day.
Supernus' ADHD Candidate Positive in 4th Phase III Study
by Zacks Equity Research
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
Why Is Mallinckrodt (MNK) Down 12.1% Since Last Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mallinckrodt (MNK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Mallinckrodt (MNK) closed the most recent trading day at $21.51, moving +0.61% from the previous trading session.
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and General Motors
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and General Motors
Buy These 6 Low Price-to-Book Value Stocks for Solid Returns
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Is Mallinckrodt public limited (MNK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MNK) Outperforming Other Medical Stocks This Year?
Is Mallinckrodt (MNK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt (MNK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Mallinckrodt (MNK) closed the most recent trading day at $23.80, moving +0.59% from the previous trading session.
Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Top Ranked Value Stocks to Buy for March 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, March 19th
Is Mallinckrodt (MNK) a Great Stock for Value Investors?
by Zacks Equity Research
Mallinckrodt (MNK) stock may be a good choice for value-oriented investors right now from multiple angles.
Add These 6 Low P/B Stocks to Your Portfolio in March
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4
by Zacks Equity Research
Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.
Implied Volatility Surging for Mallinckrodt (MNK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.